Vimal Mehta | Founder, President & Chief Executive Officer |
Richard Steinhart | Senior Vice President & Chief Financial Officer |
Robert Risinger | Vice President of Clinical Development |
Matthew Wiley | Senior Vice President & Chief Commercial Officer |
Vincent O'Neill | Senior Vice President & Chief Medical Officer |
Frank Yocca | Senior Vice President & Chief Scientific Officer |
Greg Harrison | Bank of America |
Chris Howerton | Jefferies |
Robyn Karnauskas | Truist Securities |
Sumant Kulkarni | Canaccord |
Corinne Jenkins | Goldman Sachs |
Colin Bristow | UBS |
Ram Selvaraju | H.C. Wainwright |
Anita Dushyanth | Berenberg |
Samir Devani | Rx Securities |
Good morning and welcome to BioXcel Therapeutics' Fourth Quarter and Full Year 2022 [ph] Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the presentation, there will be a question-and-answer session. [Operator Instructions] Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements subject to risks and uncertainties related to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.